Additional Society Statements
- Fiscal Year (FY) 2017 Appropriations Summary | May 2017
- Priorities for Health System Reform | January 2017
- Hypoglycemia Quality Collaborative Strategic Blueprint | October 2016
Report and Recommendations: A Resource to Increase Awareness of Hypoglycemia and Promote Activities to Reduce Its Incidence - Endocrine Society Statement on Possible Association Between GH Therapy in Childhood and Later Stroke | August 25, 2014
- Endocrine Clinical Workforce: Supply and Demand Projections | June 2014
- The Risk of Cardiovascular Events in Men Receiving Testosterone Therapy | February 7, 2014
- Society Joins Call for Review of Incretin-based Therapy for Diabetes Mellitus | June 18, 2013
- Risk of Pancreatitis Associated with Certain Diabetes Medications
- Medicare Approves Payment for Care Coordination Services
- The Endocrine Society Statement to Physicians on HRT Recommendations
- Joint Statement: The Experts Do Agree About Hormone Therapy
- Society Statement on Bisphosphonate Use for Treatment of Osteoporosis
- Society Evaluates Benefits of Bariatric Surgery and Diabetes
- Endocrine Society Clarifies FDA Review of Statin Health Effects
- Endocrine Society Statement Recommends Individualization of BMD Testing Frequency
- Statement on the Suspension of Sales of Pioglitazone in Europe
- Joint Statement on Radiation Risks to Health
- Society Response to ACP Guidelines on Intensive Insulin Therapy
- Society Response to ASBMR Report on Bisphosphonate Therapy and Atypical Femur Fractures
- Congressional Sign-On Letter to Reinstate Consultation Codes
- Endocrine Society Statement on FDA’s Avandia Ruling
- FDA Advisory Committee Decision on Avandia
- Presentations from FDA Advisory Committee hearings on Avandia
- Joint Statement on Potential Cardiovascular Risks Associated with Rosiglitazone
- Joint Statement on Radioactive Precautions Following Radioactive Iodine Therapy
- Comments to CMS on EHR Meaningful Use
- Study Findings Related to the Treatment of Hypertension in Patients with Diabetes
- Society Statement on Long-Term Use of Bisphosphonates
- The Endocrine Society Statement in Response to the Senate Finance Committee Report on Avandia
- Society Recommends Against Altering Blood Glucose Control Goals
- The Endocrine Society Statement on the Use of A1C for Diabetes Diagnosis
- Lantus (Insulin Glargine) Statement for Patients
- Statement for Providers on Potential Association of Insulin Glargine with Malignancy
- Guiding Principles for Health Reform
- The Endocrine Society Statement on ACCORD Trial
- Joint Statement on Levothyroxine and Thyroxine
- Statement to Providers on the Report Published in the New England Journal of Medicine on Avandia
- Summary of Medicare Reform Legislation